Viking Therapeutics (VKTX) Set to Announce Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, April 24th. Analysts expect Viking Therapeutics to post earnings of ($0.27) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, analysts expect Viking Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Viking Therapeutics Stock Up 0.7 %

VKTX opened at $63.85 on Tuesday. Viking Therapeutics has a 1-year low of $8.28 and a 1-year high of $99.41. The company has a fifty day moving average price of $66.27 and a two-hundred day moving average price of $33.96.

Analysts Set New Price Targets

Several equities research analysts have weighed in on VKTX shares. Oppenheimer lifted their price target on shares of Viking Therapeutics from $116.00 to $138.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $80.00 price target on shares of Viking Therapeutics in a research note on Friday, March 15th. Truist Financial lifted their price target on shares of Viking Therapeutics from $32.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. BTIG Research boosted their target price on shares of Viking Therapeutics from $100.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Finally, StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $112.25.

Insiders Place Their Bets

In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 25,000 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $28.05, for a total value of $701,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 25,000 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $28.05, for a total value of $701,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian Lian sold 269,079 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $26.87, for a total transaction of $7,230,152.73. Following the completion of the sale, the chief executive officer now directly owns 2,184,882 shares of the company’s stock, valued at $58,707,779.34. The disclosure for this sale can be found here. In the last ninety days, insiders sold 329,079 shares of company stock valued at $8,769,653. Corporate insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.